Crohn’s disease patients have specific IgG antibodies to human bacterial flagellins

Last year, researchers used a mouse model that included immune-reactive T cells from patients with Crohn’s disease in a proof-of-principle demonstration that a flagellin-directed immunotherapy might provide similar benefits in patients. Now they have moved a step closer to possible clinical testing of this treatment, with a study that describes IgG antibodies in Crohn’s disease specific for human-derived flagellins of bacteria in the Lachnospiraceae family.